Related Experiment Videos
Evolution of an inhibin A ELISA method: implications for Down's syndrome screening
E M Wallace1, J A Crossley, S C Ritoe
1Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre, Clayton, Victoria, Australia. Euan.Wallace@med.monash.edu.au
Annals of Clinical Biochemistry
|October 13, 1998
Summary
This study optimized enzyme-linked immunoassay (ELISA) for inhibin A, a prenatal marker for Down
Area of Science:
- Biochemistry
- Clinical Chemistry
- Prenatal Diagnostics
Background:
- Inhibin A is a valuable prenatal marker for Down's syndrome.
- Enzyme-linked immunoassay (ELISA) development enabled inhibin A measurement.
- Previous ELISA formats required optimization for improved performance and cost-efficiency.
Purpose of the Study:
- To detail modifications in ELISA formats for inhibin A measurement.
- To compare the performance of various ELISA formats using clinical samples.
- To assess the ability of different ELISA formats to differentiate between normal and Down's syndrome pregnancies.
Main Methods:
- Development and modification of ELISA techniques for inhibin A quantification.
- Pre-assay sample treatment variations, including sodium dodecylsulphate (SDS) at 100°C.
- Direct comparison of modified ELISA formats using clinical samples from pregnancies with and without Down's syndrome.
Main Results:
- Modified ELISA formats demonstrated improved assay performance.
- A specific format involving SDS pre-treatment at 100°C showed enhanced assay performance.
- This optimized format provided a modest improvement in differentiating Down's syndrome pregnancies from controls.
Conclusions:
- The optimized ELISA format with SDS pre-treatment offers superior performance for inhibin A measurement.
- This improved assay enhances the ability to detect Down's syndrome prenatally.
- The recommended ELISA format is suitable for broader adoption by researchers.